Towards Safety and Regulation Criteria for Clinical Applications of Decellularized Organ-Derived Matrices
Bioengineering · 30.01.2025 · 12 (2) · 136
DOI: 10.3390/bioengineering12020136 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioengineering, online erschienen am 30.01.2025. Verfasst von Elena V A van Hengel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Erasmus MC Transplant Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 193 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Topconsortium Kennis en Innovatie-Life Sciences & Health, TKI-LSH (Topconsortium Kennis en Innovatie-Life Sciences and Health).
Abstract (Originalsprache)
Whole-organ decellularization generates scaffolds containing native extracellular matrix (ECM) components with preserved tissue microarchitecture, providing a promising advancement in tissue engineering and regenerative medicine. Decellularization retains the ECM integrity which is important for supporting cell attachment, growth, differentiation, and biological function. Although there are consensus guidelines to standardize decellularization processes and ECM characterization, no specific criteria or standards regarding matrix sterility and biosafety have been established so far. This regulatory gap in safety, sterilization, and regulation criteria has hampered the clinical translation of decellularized scaffolds. In this review, we identify essential criteria for the safe clinical use of decellularized products from both human and animal sources. These include the decellularization efficacy, levels of chemical residue, preservation of ECM composition and physical characteristics, and criteria for the aseptic processing of decellularization to assure sterility. Furthermore, we explore key considerations for advancing decellularized scaffolds into clinical practice, focusing on regulatory frameworks and safety requirements. Addressing these challenges is crucial for minimizing risks of adverse reactions or infection transmission, thereby accelerating the adoption of tissue-engineered products. This review aims to provide a foundation for establishing robust guidelines, supporting the safe and effective integration of decellularized scaffolds into regenerative medicine applications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Erasmus MC Transplant Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
ORCID-Profile: Luc J W van der Laan, Monique M A Verstegen
Förderung
- Topconsortium Kennis en Innovatie-Life Sciences & Health
- TKI-LSH (Topconsortium Kennis en Innovatie-Life Sciences and Health)
Zitieren
APA
van Hengel, E. V. A., van der Laan, L. J. W., de Jonge, J., & Verstegen, M. M. A. (2025). Towards Safety and Regulation Criteria for Clinical Applications of Decellularized Organ-Derived Matrices. Bioengineering, 12(2), 136. https://doi.org/10.3390/bioengineering12020136
Vancouver
van Hengel EVA, van der Laan LJW, de Jonge J, Verstegen MMA. Towards Safety and Regulation Criteria for Clinical Applications of Decellularized Organ-Derived Matrices. Bioengineering. 2025;12(2):136. doi:10.3390/bioengineering12020136
BibTeX
@article{vanHengel2025,
author = {van Hengel, Elena V A and van der Laan, Luc J W and de Jonge, Jeroen and Verstegen, Monique M A},
title = {Towards Safety and Regulation Criteria for Clinical Applications of Decellularized Organ-Derived Matrices},
journal = {Bioengineering},
year = {2025},
volume = {12},
number = {2},
pages = {136},
doi = {10.3390/bioengineering12020136}
}
EUVIMED